98%
921
2 minutes
20
Introduction: Cognitive impairment is well-established in bipolar disorder and significantly impacts daily functioning. However, the relationship between self-evaluated cognitive functions and objective cognitive tests is inconsistent. This heterogeneity in cognitive function necessitates flexible and accessible testing methods. An Internet-based test platform can address this need. This study examines cognitive function in individuals with bipolar disorder in full or partial remission using an Internet-based test platform. It explores associations with subjective cognitive function and clinical severity.
Methods: In this cross-sectional study, the Memoro Internet-based cognitive test platform was used to assess objective cognitive functions. We recruited 84 participants with bipolar disorder type I or II in full or partial remission at the time of assessment, aged 18 to 65 years, from a bipolar outpatient clinic at a university hospital. We examined the completion rates of cognitive tests, reported technical issues, and differences between cognitively normal and impaired groups. Subjective cognition was measured using Cognitive Complaints in Bipolar Disorder Rating Assessment (COBRA).
Results: A total of 84 participants completed the Memoro assessment of objective cognitive performance. No significant differences were observed in the completion rates of cognitive subtests or reported technical issues across groups. Of the participants, 61.9% were classified as cognitively normal, while 38.1% had cognitive impairments. 86.9% reported cognitive complaints. Correlation analysis indicated relationships between cognitive complaints (COBRA), symptoms of anxiety, and verbal memory. Multiple regression analyses identify symptoms of anxiety and age as significant predictors of verbal immediate recall and cognitive complaints.
Conclusion: Objective measurements showed fewer cognitive problems than subjective reports. Additionally, anxiety symptoms may contribute to overreporting cognitive complaints.
Clinical Registration: ClinicalTrials.gov identifier: NCT04454073.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/acps.70031 | DOI Listing |
Int J Soc Psychiatry
September 2025
Psychiatry Department, Ege University School of Medicine, İzmir, Turkey.
Background: Bipolar disorder (BD) is a complex mood disorder among the leading causes of disability worldwide. Internalized stigma refers to the awareness of negative stereotypes adopted by society and the agreement with these judgments, often associated with impaired functionality and social adaptation. Studies examining internalized stigma and related factors in BD are limited.
View Article and Find Full Text PDFFront Nutr
August 2025
Faculty of Medicine, Department of Psychiatry, Medical University of Gdańsk, Gdańsk, Poland.
Unlabelled: Mood disorders, including major depressive disorder (MDD) and bipolar disorder (BP), significantly impact global health, with MDD affecting over 300 million people and BP affecting approximately 2% of the world's population. Ketamine, originally an anesthetic, has emerged as a promising treatment for patients with treatment-resistant depression (TRD), due to its unique pharmacological properties, such as N-methyl-D-aspartate (NMDA) receptor antagonism and anti-inflammatory effects. The potential of ketamine in treating depression has sparked debate regarding its effects on appetite.
View Article and Find Full Text PDFAlpha Psychiatry
August 2025
Department of Psychiatry, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, 34147 Istanbul, Turkey.
Objective: In bipolar disorder, residual mood symptoms often persist even during the euthymic period, impairing functionality in 30-60% of patients in clinical remission. Addressing residual symptoms is critical as they are linked to reduced functionality and subjective wellbeing. This cross-sectional study aimed to determine the relationship between mindful attention awareness (MASS) and residual symptom severity in bipolar I disorder.
View Article and Find Full Text PDFJ Appl Toxicol
September 2025
Department of Drug and Cosmetics Technology, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, Sosnowiec, Poland.
Phenothiazine derivatives have been used for decades as antipsychotic drugs in multiple mental health and physical conditions treatment (schizophrenia, mania in bipolar disorder, and psychosis). Epidemiological studies have shown that people with schizophrenia are less likely to suffer from cancer, which indicates the ability of antipsychotics to inhibit the development of cancer cells. It is our third review about the impact of phenothiazine derivatives on cell death.
View Article and Find Full Text PDFComput Med Imaging Graph
August 2025
Beijing Huilongguan Hospital, Peking University Huilongguan Clinical Medical School, Beijing 100096, China. Electronic address:
Bipolar disorder (BD) is a debilitating mental illness characterized by significant mood swings, posing a substantial challenge for accurate diagnosis due to its clinical complexity. This paper presents CS2former, a novel approach leveraging a dual channel-spatial feature extraction module within a Transformer model to diagnose BD from resting-state functional MRI (Rs-fMRI) and T1-weighted MRI (T1w-MRI) data. CS2former employs a Channel-2D Spatial Feature Aggregation Module to decouple channel and spatial information from Rs-fMRI, while a Channel-3D Spatial Attention Module with Synchronized Attention Module (SAM) concurrently computes attention for T1w-MRI feature maps.
View Article and Find Full Text PDF